Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01928017|
Recruitment Status : Completed
First Posted : August 23, 2013
Last Update Posted : December 3, 2014
This is a prospective observational clinical study to characterise abnormalities of thromboelastography (TEG) parameters in patients with chemotherapy-induced thrombocytopenia. The investigators are also studying the relationship between Multiplate analysis and bleeding in these patients and the effect of platelet transfusions on thrombopoietin level and percent reticulated platelets.
The investigators' hypothesis is that changes in TEG-parameters reflect the patients tendency to bleed.
|Condition or disease|
|Bone Marrow Diseases Lymphoma|
Thrombocytopenic patients are followed with blood samples (thromboelastography, Multiplate, haematology) daily, Monday to Friday for up to 30 days.
In addition bleeding evaluation is done daily ,using a standardized questionnaire. The questionnaire is filled out after interview of the patient, and som times next of kin and nurses. Nurse journals and medical journals are also used to fill in the questionnaires.
For thromboelastography (TEG) we are looking at which parameters are abnormal, and if there is other factors than platelet count that influence the results. We will also compare TEG from days with and without bleeding, to see if they differ.
For Multiplate we are doing a pilot study to see whether this analysis can be of any use at all in this group of patients. We are looking into which factors that influence the Multiplate result, and if we can see a difference in the results if the patient is bleeding.
For reticulated platelets and thrombopoietin we are studying the levels related to platelet transfusions.
|Study Type :||Observational|
|Actual Enrollment :||13 participants|
|Official Title:||Monitoring of Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia|
|Study Start Date :||June 2013|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||June 2014|
- MA [ Time Frame: 1 year ]To characterise changes in the TEG-parameter MA in patients with chemotherapy-induced thrombocytopenia
- Reticulated platelets percent [ Time Frame: 1 year ]To investigate the effect of platelet transfusions on percent reticulated platelets.
- Bleeding [ Time Frame: 1 year ]
To investigate the relationship between TEG-parameters, bleeding and need for platelet transfusion.
To investigate the influence of HLA antibodies on risk of bleeding and transfusion complications.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01928017
|Haukeland University Hospital|
|Bergen, Norway, 5021|
|Study Director:||Tor A Hervig, dr.med||University of Bergen|